Eiko Lifesciences Ltd (EIKO) — shareholding pattern, promoter holding, financials and share price
About Eiko Lifesciences Ltd (EIKO)
Eiko Lifesciences Ltd operates in the Specialty Chemicals industry, within the Chemicals sector. It trades on the NSE as EIKO and on the BSE under scrip code 540204. Its ISIN is INE666Q01016.
Incorporated in 2021, Eiko LifeSciences Ltd manufacturing & sells Specialty Chemical and Fine Chemicals [1]
Eiko Lifesciences Limited specializes in manufacturing and exporting specialty chemicals and pharma intermediates, serving both Indian and global markets.
Originally founded as Narendra Investments (Delhi) Limited, the company shifted to its current name and business focus in 2021, marking a significant transformation.
Listed peers in Specialty Chemicals: Deepak Chemtex Ltd, Alkali Metals Ltd, Technichem Organics Ltd, Bhatia Colour Chem Ltd, Mehul Colours Ltd, Hardcastle & Waud Mfg Co Ltd.
Valuation & Returns
10 Jul 2026At ₹49.2 a share on 10 Jul 2026, Eiko Lifesciences Ltd (EIKO) was valued at a price-to-earnings ratio of 13.27x against an industry P/E of 45.11x and a price-to-book of 1,24,288.33x. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 13.27x
- Industry P/E
- 45.11x
- P/B
- 1,24,288.33x
- EPS (TTM)
- ₹3.71
- Debt / equity
- 0.05x
- Dividend yield
- 0%
- EBITDA margin
- 16.05%
- 52-week range
- ₹49 – ₹50.2
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Eiko Lifesciences Ltd (EIKO) reported revenue of ₹52.71 crore, net profit of ₹5.33 crore and earnings per share of ₹3.14. That compares with revenue of ₹37.66 crore and net profit of ₹2.32 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹18.34 crore and net profit ₹1.5 crore (consolidated).
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 2.36 | 4.27 | 10.4 | 37.66 | 52.71 |
| Net profit (₹ cr) | 0.2 | -0.78 | -3.62 | 2.32 | 5.33 |
| EPS (₹) | 0.31 | -0.69 | -2.98 | 1.86 | 3.14 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 57.04% | - | 8.54% | 16.33% |
| Profit growth | 40.83% | 68.60% | 35.12% | 132.00% |
| Stock price CAGR | - | -7% | -2% | -8% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 39.91% of Eiko Lifesciences Ltd (EIKO) (unchanged from the previous quarter). Market capitalisation was ₹71 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2016.
Largest disclosed public shareholders in Jun 2026: 2B BLACK BIO LLP 9.66%, ASHIKA GLOBAL FINANCE PRIVATE LIMITED 4.19%, ASHOK VISHWANATH HIREMATH 3.72%, SUSHILA PARASKUMAR DAGA 2.78%, SIVANESAN SELLAPPAN 2.02%, JOYANTA KUMAR JANA 1.99%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 39.91% | - | - | - | 60.09% |
| Mar 2026 | 39.91% | - | - | - | 60.09% |
| Dec 2025 | 37.17% | - | - | - | 62.83% |
| Sep 2025 | 37.17% | - | - | - | 62.83% |
| Jun 2025 | 36.74% | - | - | - | 63.26% |
| Mar 2025 | 36.23% | - | - | - | 63.77% |
| Dec 2024 | 31.27% | - | - | - | 68.73% |
| Sep 2024 | 24.4% | - | - | - | 75.6% |